title: [Metastasized prostate cancer. Position paper on the use of chemotherapy].
abstract: BACKGROUND
  Antihormonal and cytotoxic therapy options are available for the therapy of metastasized prostate cancer (mPC). Because no comparative studies are available, especially for castration-resistant prostate cancer (mCRCP), it remains unclear which patients will profit best from which therapy.
  
  
  OBJECTIVE
  Previous data on the sequence of the various therapy options show that correct selection of the first line therapy for mCRPC can have an influence on the prognosis of the patient. In this position paper the various therapy options are critically illustrated and the clinical and pathohistological criteria for selection of the first line therapy of mCRPC are discussed.
  
  
  RESULTS
  Molecular markers are an important aid for future patient selection and individualized therapy for optimal use of the available forms of therapy.
authors.affiliation: Klinik für Urologie und Kinderurologie, Universitätsklinikum des Saarlandes und Medizinische Fakultät der Universität des Saarlandes, Kirrbergerstraße 1, 66424, Homburg, Deutschland, carsten.ohlmann@uks.eu.
authors.forename: C-H
authors.initials: CH
authors.lastname: Ohlmann
authors.forename: S
authors.initials: S
authors.lastname: Duensing
authors.forename: R
authors.initials: R
authors.lastname: Eichenauer
authors.forename: F
authors.initials: F
authors.lastname: König
authors.forename: S
authors.initials: S
authors.lastname: Machtens
authors.forename: M
authors.initials: M
authors.lastname: Schostak
authors.forename: C
authors.initials: C
authors.lastname: Thomas
authors.forename: P
authors.initials: P
authors.lastname: Albers
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002277:Carcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000556:secondary*; D004358:Drug Therapy / Q000592:standards; D005858:Germany; D006801:Humans; D008297:Male; D008495:Medical Oncology / Q000592:standards*; D017410:Practice Guidelines as Topic; D064129:Prostatic Neoplasms, Castration-Resistant / Q000175:diagnosis / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents